ICU Medical (NASDAQ:ICUI) PT Raised to $190.00

ICU Medical (NASDAQ:ICUI) had its target price lifted by Raymond James from $158.00 to $190.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical instruments supplier’s stock. Raymond James’ price target would indicate a potential upside of 11.49% from the company’s current price.

ICUI has been the topic of a number of other research reports. KeyCorp raised their price target on shares of ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.00.

ICU Medical Price Performance

ICUI opened at $170.42 on Thursday. The stock has a fifty day moving average price of $142.14 and a 200 day moving average price of $118.04. The company has a current ratio of 2.41, a quick ratio of 1.08 and a debt-to-equity ratio of 0.76. ICU Medical has a 1 year low of $78.28 and a 1 year high of $171.63. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of -69.56 and a beta of 0.65.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million during the quarter, compared to analyst estimates of $556.64 million. During the same period in the previous year, the company earned $1.58 EPS. The firm’s revenue was up 8.6% on a year-over-year basis. Analysts forecast that ICU Medical will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the sale, the vice president now directly owns 4,482 shares of the company’s stock, valued at $645,901.02. The disclosure for this sale can be found here. Insiders have sold 28,552 shares of company stock worth $4,537,802 in the last quarter. 6.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its stake in ICU Medical by 14.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock valued at $19,227,000 after acquiring an additional 23,816 shares during the period. Jump Financial LLC acquired a new position in shares of ICU Medical in the fourth quarter valued at $352,000. Dimensional Fund Advisors LP lifted its position in ICU Medical by 4.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 220,624 shares of the medical instruments supplier’s stock worth $22,005,000 after purchasing an additional 9,196 shares during the period. Principal Financial Group Inc. boosted its stake in ICU Medical by 37.8% during the fourth quarter. Principal Financial Group Inc. now owns 107,335 shares of the medical instruments supplier’s stock worth $10,706,000 after buying an additional 29,464 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in ICU Medical in the 4th quarter valued at $351,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.